AQR Capital Management LLC Sells 19,600 Shares of OPKO Health, Inc. (NASDAQ:OPK)

AQR Capital Management LLC decreased its position in OPKO Health, Inc. (NASDAQ:OPK) by 19.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 79,839 shares of the biotechnology company’s stock after selling 19,600 shares during the quarter. AQR Capital Management LLC’s holdings in OPKO Health were worth $100,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. CIBC Asset Management Inc lifted its position in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 8,978 shares during the last quarter. Virtu Financial LLC bought a new stake in OPKO Health in the first quarter valued at approximately $26,000. Headlands Technologies LLC bought a new stake in OPKO Health in the first quarter valued at approximately $47,000. American Century Companies Inc. bought a new stake in OPKO Health in the second quarter valued at approximately $112,000. Finally, Comerica Bank lifted its position in OPKO Health by 125.0% in the first quarter. Comerica Bank now owns 90,000 shares of the biotechnology company’s stock valued at $108,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 64.63% of the company’s stock.

Insider Activity at OPKO Health

In related news, major shareholder Opko Health, Inc. sold 100,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $31.82, for a total transaction of $3,182,000.00. Following the sale, the insider now directly owns 2,871,570 shares of the company’s stock, valued at $91,373,357.40. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 586,444 shares of company stock valued at $19,494,627 over the last ninety days. Insiders own 47.26% of the company’s stock.

OPKO Health Trading Up 0.7 %

NASDAQ OPK opened at $1.47 on Friday. OPKO Health, Inc. has a 12 month low of $0.85 and a 12 month high of $1.75. The stock has a market cap of $1.02 billion, a P/E ratio of -4.19 and a beta of 1.63. The stock’s fifty day moving average price is $1.55 and its 200-day moving average price is $1.40. The company has a current ratio of 1.63, a quick ratio of 1.36 and a debt-to-equity ratio of 0.13.

OPKO Health (NASDAQ:OPK) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.08. OPKO Health had a negative return on equity of 17.67% and a negative net margin of 33.79%. The firm had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $184.70 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. The company’s quarterly revenue was down 31.3% on a year-over-year basis. As a group, equities analysts forecast that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently commented on OPK. StockNews.com upgraded OPKO Health to a “sell” rating in a report on Saturday, July 27th. Piper Sandler restated an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Barrington Research restated an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a report on Friday, September 20th. Finally, HC Wainwright restated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.